Ras Family Signaling: Therapeutic Targeting
暂无分享,去创建一个
[1] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[2] Frank McCormick,et al. The GTPase superfamily: a conserved switch for diverse cell functions , 1990, Nature.
[3] G. Prendergast,et al. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity , 1995, Molecular and cellular biology.
[4] N. Rosen,et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.
[5] C. Der,et al. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. , 1996, Oncogene.
[6] S. Cantor,et al. Evidence for a Ras/Ral signaling cascade. , 1996, Trends in biochemical sciences.
[7] E. Lesnik,et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] C. Marshall. Ras effectors. , 1996, Current opinion in cell biology.
[9] W. R. Bishop,et al. K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.
[10] M. Lewis,et al. Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo * , 1997, The Journal of Biological Chemistry.
[11] J Downward,et al. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. , 1997, Trends in biochemical sciences.
[12] S. Sebti,et al. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines , 1997, Oncogene.
[13] W. R. Bishop,et al. Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I* , 1997, The Journal of Biological Chemistry.
[14] Walter A. Korfmacher,et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. , 1998, Cancer research.
[15] N. Rosen,et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] S. Sebti,et al. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts , 1998, Oncogene.
[17] W. Kabsch,et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] E K Rowinsky,et al. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Y. Fu,et al. Association of K-ras mutations with p16 methylation in human colon cancer. , 1999, Gastroenterology.
[20] Alan R. Saltiel,et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.
[21] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[22] P. Casey,et al. Enzymology and biology of CaaX protein prenylation. , 1999, Recent progress in hormone research.
[23] M. Marshall,et al. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. , 1999, International journal of oncology.
[24] T. Jessell,et al. RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors , 2000, Molecular and Cellular Biology.
[25] S. Sebti,et al. Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice* , 2000, The Journal of Biological Chemistry.
[26] Y. Kloog,et al. RAS inhibitors: potential for cancer therapeutics. , 2000, Molecular medicine today.
[27] J. Otto,et al. Targeted Inactivation of the Isoprenylcysteine Carboxyl Methyltransferase Gene Causes Mislocalization of K-Ras in Mammalian Cells* , 2000, The Journal of Biological Chemistry.
[28] R. Muschel,et al. Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS1 , 2000, Radiation research.
[29] C. Erlichman,et al. Comparison of potential markers of farnesyltransferase inhibition. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] C. Bowden,et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] W. Yung,et al. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. , 2000, Neuro-oncology.
[32] D. Bar-Sagi,et al. Ras and Rho GTPases A Family Reunion , 2000, Cell.
[33] S. Sebti,et al. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues , 2000, Expert opinion on investigational drugs.
[34] C. Der,et al. Understanding Ras: 'it ain't over 'til it's over'. , 2000, Trends in cell biology.
[35] S. Chong,et al. Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. , 2000, Journal of medicinal chemistry.
[36] W. R. Bishop,et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo , 2000, Cancer Chemotherapy and Pharmacology.
[37] W. R. Bishop,et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. , 2000, Cancer research.
[38] J. Karp,et al. Current status of clinical trials of farnesyltransferase inhibitors , 2001, Current opinion in oncology.
[39] N. Normanno,et al. The role of EGF-related peptides in tumor growth. , 2001, Frontiers in bioscience : a journal and virtual library.
[40] A. Cox,et al. Farnesyltransferase inhibitors: potential role in the treatment of cancer. , 2001, Drugs.
[41] R. Lothe,et al. Intradermal ras peptide vaccination with granulocyte‐macrophage colony‐stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma , 2001, International Journal of Cancer.
[42] A. Kral,et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. , 2001, Cancer research.
[43] P. Casey,et al. Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. , 2001, Bioorganic & medicinal chemistry letters.
[44] J. Karp,et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.
[45] C. Bowden,et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.
[46] G. Prendergast,et al. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] C. Arteaga,et al. Inhibitors of HER2/neu (erbB-2) signal transduction. , 2001, Seminars in oncology.
[48] G. Prendergast,et al. Farnesyltransferase inhibitors: mechanism and applications , 2001, Expert opinion on investigational drugs.
[49] J. Nemunaitis,et al. A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma , 2001, Cancer.
[50] G. Bollag,et al. Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.
[51] N. Rosen,et al. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. , 2001, Cancer research.
[52] J. Baselga,et al. Mechanism of action of trastuzumab and scientific update. , 2001, Seminars in oncology.
[53] S. Hahn,et al. Ras inhibitors and radiation therapy. , 2001, Seminars in radiation oncology.
[54] A. Guha,et al. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. , 2001, Cancer research.
[55] K. Resing,et al. Pharmacologic inhibitors of MKK1 and MKK2. , 2001, Methods in enzymology.
[56] C. Der,et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. , 2002, Genes & development.
[57] A. Balmain,et al. Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation , 2002, Molecular and Cellular Biology.
[58] A. Dritschilo,et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[60] Jie Zhang,et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[61] A. Adjei,et al. Farnesyl transferase inhibitors as anticancer agents. , 2002, European journal of cancer.
[62] R. Bernards,et al. Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.
[63] John G. Collard,et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours , 2002, Nature.
[64] E. Rowinsky,et al. The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.
[65] Sheo B. Singh,et al. Current progress on farnesyl protein transferase inhibitors. , 2002, Current opinion in drug discovery & development.
[66] L. Siu,et al. Rationale for Ras and raf-kinase as a target for cancer therapeutics. , 2002, Current pharmaceutical design.
[67] F. Caponigro. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. , 2002, Anti-cancer drugs.
[68] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[69] S. Sebti,et al. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[70] J. Sebolt-Leopold,et al. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. , 2002, Trends in molecular medicine.
[71] P. Workman,et al. HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.
[72] J. Dancey. Agents targeting ras signaling pathway. , 2002, Current pharmaceutical design.
[73] John M. Lambert,et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism , 2002, Nature Cell Biology.
[74] M. Ranson. Epidermal growth factor receptor tyrosine kinase inhibitors , 2004, British Journal of Cancer.